The difficult pathway of natriuretic peptides in heart failure

El difícil camino de los péptidos natriuréticos en la insuficiencia cardiaca


  • Omar Augusto Diaz Cucho Hospital Alberto Barton Thompson, Callao, Perú



Heart failure, natriuretic peptides, sacubitril-valsartan, neprilysin


This review is carried out on the role of natriuretic peptides and attempts to use them properly, as a treatment, their functioning in the pathophysiology of heart failure with depressed systolic function was better understood. It is recounts its journey through multiple failed studies, explaining the reasons for its failures, until it achieved the desired success with the combination of sacubitril/valsartan. This produced a paradigm shift in the management of heart failure.


Download data is not yet available.

Author Biography

Omar Augusto Diaz Cucho, Hospital Alberto Barton Thompson, Callao, Perú

Médico cardiólogo

Máster en Insuficiencia Cardíaca


Hartupee J, Mann DL. Neurohormonal activation in heart failure with reduced ejection fraction. Nat Rev Cardiol. 2017;14(1):30-8.

Miranda D, O´Gara P, Lilly L. Insuficiencia cardiaca. En: Cardiología Bases Fisiopatológicas De Las Cardiopatías. 6°. Wolters Kluwer; 2015. p. 220-48.

Volpe M. Natriuretic peptides and cardio-renal disease. Int J Cardiol. 2014;176(3):630-9.

SOLVD Investigators, Yusuf S, Pitt B, Davis CE, Hood WB, Cohn JN. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325(5):293-302.

Granger CB, McMurray JJV, Yusuf S, Held P, Michelson EL, Olofsson B, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet Lond Engl. 2003;362(9386):772-6.

CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet Lond Engl. 1999;353(9146):9-13.

Zannad F, McMurray JJV, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364(1):11-21.

Sacks CA, Jarcho JA, Curfman GD. Paradigm shifts in heart-failure therapy--a timeline. N Engl J Med. 2014;371(11):989-91.

Mosterd A, Hoes A. Clinical epidemiology of heart failure. Heart 2007. 2007;93(9):1137-41.

Jaagosild P, Dawson NV, Thomas C, Wenger NS, Tsevat J, Knaus WA, et al. Outcomes of acute exacerbation of severe congestive heart failure: quality of life, resource use, and survival. SUPPORT Investigators. The Study to Understand Prognosis and Preferences for Outcomes and Risks of Treatments. Arch Intern Med. 1998;158(10):1081-9.

Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Borden WB, et al. Heart disease and stroke statistics--2013 update: a report from the American Heart Association. Circulation. 2013;127(1):e6-245.

Volpe M, Carnovali M, Mastromarino V. The natriuretic peptides system in the pathophysiology of heart failure: from molecular basis to treatment. Clin Sci. 2016;130(2):57-77.

Jhund PS, McMurray JJV. The neprilysin pathway in heart failure: a review and guide on the use of sacubitril/valsartan. Heart Br Card Soc. 2016;102(17):1342-7.

Díez J. Chronic heart failure as a state of reduced effectiveness of the natriuretic peptide system: implications for therapy. Eur J Heart Fail. 2017;19(2):167-76.

Colucci WS, Elkayam U, Horton DP, Abraham WT, Bourge RC, Johnson AD, et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. N Engl J Med. 2000;343(4):246-53.

Sackner-Bernstein JD, Kowalski M, Fox M, Aaronson K. Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. JAMA. 2005;293(15):1900-5.

O’Connor CM, Starling RC, Hernandez AF, Armstrong PW, Dickstein K, Hasselblad V, et al. Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med. 2011;365(1):32-43.

Hata N, Seino Y, Tsutamoto T, Hiramitsu S, Kaneko N, Yoshikawa T, et al. Effects of carperitide on the long-term prognosis of patients with acute decompensated chronic heart failure: the PROTECT multicenter randomized controlled study. Circ J Off J Jpn Circ Soc. 2008;72(11):1787-93.

Rademaker MT, Richards AM. Cardiac natriuretic peptides for cardiac health. Clin Sci Lond Engl 1979. 2005;108(1):23-36.

Masson S, Latini R, Anand IS, Vago T, Angelici L, Barlera S, et al. Direct comparison of B-type natriuretic peptide (BNP) and amino-terminal proBNP in a large population of patients with chronic and symptomatic heart failure: the Valsartan Heart Failure (Val-HeFT) data. Clin Chem. 2006;52(8):1528-38.

Shima M, Seino Y, Torikai S, Imai M. Intrarenal localization of degradation of atrial natriuretic peptide in isolated glomeruli and cortical nephron segments. Life Sci. 1988;43(4):357-63.

Potter LR. Natriuretic Peptide Metabolism, Clearance and Degradation. FEBS J. 2011;278(11):1808-17.

Fielitz J, Dendorfer A, Pregla R, Ehler E, Zurbrügg HR, Bartunek J, et al. Neutral endopeptidase is activated in cardiomyocytes in human aortic valve stenosis and heart failure. Circulation. 2002;105(3):286-9.

Bayes-Genis A, Lupón J. Neprilisina: indicaciones, expectativas y retos. Rev Esp Cardiol. 2016;69(7):647-9.

Wills B, Prada LP, Rincón A, Buitrago AF. Inhibición dual de la neprilisina y del receptor de la angiotensina (ARNI): una alternativa en los pacientes con falla cardiaca. Rev Colomb Cardiol. 2016;23(2):120-7.

Bevan EG, Connell JM, Doyle J, Carmichael HA, Davies DL, Lorimer AR, et al. Candoxatril, a neutral endopeptidase inhibitor: efficacy and tolerability in essential hypertension. J Hypertens. 1992;10(7):607-13.

Richards AM, Wittert GA, Crozier IG, Espiner EA, Yandle TG, Ikram H, et al. Chronic inhibition of endopeptidase 24.11 in essential hypertension: evidence for enhanced atrial natriuretic peptide and angiotensin II. J Hypertens. 1993;11(4):407-16.

von Lueder TG, Atar D, Krum H. Current role of neprilysin inhibitors in hypertension and heart failure. Pharmacol Ther. 2014;144(1):41-9.

Abassi Z, Golomb E, Keiser HR. Neutral endopeptidase inhibition increases the urinary excretion and plasma levels of endothelin. Metabolism. 1992;41(7):683-5.

Erdös EG, Skidgel RA. Neutral endopeptidase 24.11 (enkephalinase) and related regulators of peptide hormones. FASEB J Off Publ Fed Am Soc Exp Biol. 1989;3(2):145-51.

Skidgel RA, Engelbrecht S, Johnson AR, Erdös EG. Hydrolysis of substance P and neurotensin by converting enzyme and neutral endopeptidase. Peptides. 1984;5(4):769-76.

Stephenson SL, Kenny AJ. Metabolism of neuropeptides. Hydrolysis of the angiotensins, bradykinin, substance P and oxytocin by pig kidney microvillar membranes. Biochem J. 1987;241(1):237-47.

von Lueder TG, Sangaralingham SJ, Wang BH, Kompa AR, Atar D, Burnett JC, et al. Renin-Angiotensin Blockade Combined With Natriuretic Peptide System Augmentation: Novel Therapeutic Concepts to Combat Heart Failure. Circ Heart Fail. 2013;6(3):594-605.

Trippodo NC, Fox M, Monticello TM, Panchal BC, Asaad MM. Vasopeptidase inhibition with omapatrilat improves cardiac geometry and survival in cardiomyopathic hamsters more than does ACE inhibition with captopril. J Cardiovasc Pharmacol. 1999;34(6):782-90.

Kostis JB, Packer M, Black HR, Schmieder R, Henry D, Levy E. Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial. Am J Hypertens. 2004;17(2):103-11.

Packer M, Califf RM, Konstam MA, Krum H, McMurray JJ, Rouleau J-L, et al. Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation. 2002;106(8):920-6.

Nussberger J, Cugno M, Amstutz C, Cicardi M, Pellacani A, Agostoni A. Plasma bradykinin in angio-oedema. Lancet Lond Engl. 1998;351(9117):1693-7.

Richards AM, Wittert GA, Espiner EA, Yandle TG, Ikram H, Frampton C. Effect of inhibition of endopeptidase 24.11 on responses to angiotensin II in human volunteers. Circ Res. 1992;71(6):1501-7.

Volpe M, Carnovali M, Mastromarino V. The natriuretic peptides system in the pathophysiology of heart failure: from molecular basis to treatment. Clin Sci (Lond). 2016;130(2):57-77.

Gu J, Noe A, Chandra P, Al-Fayoumi S, Ligueros-Saylan M, Sarangapani R, et al. Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi). J Clin Pharmacol. 2010;50(4):401-14.

Bloch MJ, Basile JN. Combination angiotensin receptor blocker-neutral endopeptidase inhibitor provides additive blood pressure reduction over angiotensin receptor blocker alone. J Clin Hypertens Greenwich Conn. 2010;12(10):809-12.

Ruilope LM, Dukat A, Böhm M, Lacourcière Y, Gong J, Lefkowitz MP. Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study. Lancet Lond Engl. 2010;375(9722):1255-66.

McMurray JJV, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993-1004.

Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016;18(8):891-975.

Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Colvin MM, et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2017;136(6):e137-61.


2023-09-14 — Updated on 2023-12-06


How to Cite

Díaz Cucho, O. A. (2023). The difficult pathway of natriuretic peptides in heart failure: El difícil camino de los péptidos natriuréticos en la insuficiencia cardiaca. Revista De La Facultad De Medicina Humana, 23(3), 140–147. (Original work published September 14, 2023)